Overview
- Gallup reports adult obesity at 37% in 2025, down from 39.9% in 2022, an estimated 7.6 million fewer obese adults based on self‑reported BMI from nearly 17,000 respondents.
- Self‑reported use of injectable GLP‑1 drugs for weight loss rose to 12.4% from 5.8% in February 2024, with usage higher among women (15.2%) than men (9.7%).
- Declines are concentrated among adults ages 40–64, the cohorts with the highest reported GLP‑1 use, and women have seen larger reductions than men since 2022.
- Diagnosed diabetes reached a reported high of 13.8% in 2025, which Gallup notes may not fall quickly because diabetes is a chronic condition.
- Access is narrowing as many insurers and employers limit coverage; GoodRx data show most plans exclude Zepbound, CVS Caremark has steered formularies toward Wegovy, and patients without coverage often face about $500 per month out of pocket.